Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
WuXi Biologics and Vertex (VRTX) signed a license and research service agreement dated Feb 2, 2026, covering an innovative trispecific T‑cell Engager (TCE) for B‑cell mediated autoimmune diseases.
Vertex receives exclusive global development and commercialization rights at the preclinical stage; WuXi Biologics will receive an upfront payment, potential development/regulatory/sales milestones and royalties, and will provide contract R&D services on next‑generation TCEs.
Satellos (GBIO) appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on January 29, 2026.
Ms. Paone joins from Generation Bio where she served as Chief Operating Officer and previously led regulatory strategy at Vertex, including work on Kalydeco and Orkambi. Satellos says her hire supports advancement of two SAT-3247 clinical studies in adult and pediatric DMD populations.
Vertex (NASDAQ: VRTX) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. The company will host a conference call and webcast at 4:30 p.m. ET.
Dial-in numbers: (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The live webcast will be available in the Investors section of Vertex's website and an archived webcast will be posted. Participants are recommended to register at least 15 minutes before the webcast to ensure timely connection.
Vertex (Nasdaq: VRTX) provided business and pipeline updates ahead of investor meetings and a webcast at the J.P. Morgan Healthcare Conference on January 12, 2026. Key commercial milestones in 2025 include >$100 million in CASGEVY revenue and >500,000 JOURNAVX prescriptions with access for ~200 million covered lives. Vertex reported multiple regulatory and clinical milestones: a rolling BLA for povetacicept with priority review voucher and Breakthrough designation, RAINIER full enrollment, planned pivotal submissions for CASGEVY pediatric use in H1 2026, and several mid/late‑stage studies delivering data or completing enrollment across CF, renal, pain, and other programs.
Vertex (Nasdaq: VRTX) announced that Dr. Reshma Kewalramani, CEO and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. ET / 2:15 p.m. PT.
A live webcast of management's remarks will be available in the company's Investors > News and Events section at www.vrtx.com, and a replay will be archived on the website.
Vertex (Nasdaq: VRTX) presented first-ever pivotal data for CASGEVY in children ages 5–11 with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) at ASH and announced plans for global regulatory submissions in 1H 2026.
In 5–11 patients, SCD results showed VOC-free outcomes (VF12) in all patients with sufficient follow-up and TDT patients achieved transfusion independence (TI12) in all with sufficient follow-up. Longer-term data in ages ≥12 continued to show durable benefits: 100% VF12 (45/45) in SCD and 98.2% TI12 (55/56) in TDT with multi-year mean durations. Safety was consistent with myeloablative conditioning and autologous transplant; one pediatric death related to conditioning-associated veno-occlusive disease was reported.
Vertex (Nasdaq: VRTX) announced that senior management will participate in Citi’s 2025 Global Healthcare Conference on Wednesday, December 3, 2025 at 9:00 a.m. ET.
Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will take part in a fireside chat. A live webcast of management’s remarks will be available on Vertex’s investor website, and a replay will be archived on the company's site.
Vertex (Nasdaq: VRTX) presented updated 48-week Phase 1/2 RUBY-3 data showing 64% mean UPCR reduction in IgA nephropathy (IgAN) and 82% mean UPCR reduction in primary membranous nephropathy (pMN) at the 80 mg dose, with eGFR stabilization across both cohorts (IgAN change +3.3±3.1 mL/min/1.73m2; pMN change -0.3±3.4 mL/min/1.73m2).
Clinical outcomes included 53% clinical remission in IgAN and 40% complete remission in pMN; 90% hematuria resolution in a subgroup. Pove was generally well tolerated with no serious adverse events related to the drug. Regulatory progress: FDA Breakthrough Therapy for IgAN, Fast Track for pMN, Phase 3 RAINIER fully enrolled, and Vertex plans a BLA rolling submission this year with intent to use a priority review voucher.
Vertex (NASDAQ: VRTX) reported Q3 2025 total revenue of $3.08 billion, up 11% year-over-year, driven by cystic fibrosis (CF) therapies and early launches. U.S. revenue was $1.98 billion (+15%); ex-U.S. was $1.10 billion (+4%). Cash and marketable securities totaled $12.0 billion as of Sept 30, 2025. Vertex refined FY2025 guidance to $11.9–$12.0 billion revenue and raised combined GAAP operating expense guidance to $5.65–$5.8 billion (non-GAAP $5.0–$5.1 billion).
Pipeline highlights: povetacicept Phase 3 IgAN fully enrolled and first BLA module on track by end of 2025; continued progress across CF, CASGEVY and JOURNAVX launches.
Vertex (Nasdaq: VRTX) announced that CEO Reshma Kewalramani will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 10:15 a.m. ET.
A live webcast of management's remarks will be available via the company's Investors site under News and Events, and a replay will be archived on the Vertex website.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
